About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

New Class of Antibiotics to Fight Drug Resistance Identified

by Colleen Fleiss on April 9, 2018 at 1:48 AM
New Class of Antibiotics to Fight Drug Resistance Identified

Odilorhabdins, the new class of antibiotics which may combat drug resistant, hard to treat infections have been discovered by researchers.

The antibiotic called odilorhabdins, or ODLs, are produced by symbiotic bacteria found in soil-dwelling nematode worms that colonise insects for food.

Advertisement


According to the World Health Organisation, antibiotic resistant is one of the biggest threats to global health today and a significant contributor to longer hospital stays, higher medical costs, and increased mortality.

The bacteria help to kill the insect and, importantly, secretes the antibiotic to keep competing bacteria away, said researchers from the University of Illinois (UIC) at Chicago and Nosopharm, a France-based biotechnology company.
Advertisement

To identify the antibiotic, the team screened 80 cultured strains of the bacteria for antimicrobial activity.

They found that ODLs act on the ribosome -- the molecular machine of individual cells that makes the proteins it needs to function -- of bacterial cells.

"Like many clinically useful antibiotics, ODLs work by targeting the ribosome," said Yury Polikanov, Assistant Professor at the UIC.

"But ODLs are unique because they bind to a place on the ribosome that has never been used by other known antibiotics," Polikanov added.

Further, the team found that when bound to the ribosome, the new antibiotic disrupts its ability to interpret and translate genetic code.

"When ODLs are introduced to the bacterial cells, they impact the reading ability of the ribosome and cause the ribosome to make mistakes when it creates new proteins," said Alexander Mankin, Professor at the University.

"The bactericidal mechanism of ODLs and the fact that they bind to a site on the ribosome, not exploited by any known antibiotic, are very strong indicators that ODLs have the potential to treat infections that are unresponsive to other antibiotics," Mankin noted.

Source: IANS
Font : A-A+

Advertisement

Advertisement
Advertisement

Recommended Readings

Latest Drug News

WHO Approves R21/Matrix-M, the World's Second Malaria Vaccine
R21/Matrix-M, the world's second malaria vaccine is readily deployable, and cost-effective making it prepared for distribution in areas where it is most essential.
New Inverse Vaccine Sparks Hope in Diabetes, Arthritis, and Crohn's Disease
The reverse vaccine uses the liver's natural "non-target" signals to prevent autoimmune responses against naturally decaying cells.
Projected Growth: Psychedelic Drug Market Anticipated to Hit $7.2 Billion by 2029
The psychedelic market set for remarkable growth, projected to hit $7.2B by 2029 with a strong 55% CAGR.
Promising ALS Drug Candidate Extends Lifespan
The study explores whether CDNF could influence the progression of ALS in rodent models and to elucidate the mechanism through which it operates.
Amoxicillin-Calvulanate Vs Amoxicillin Preference in Child Sinusitis Treatment
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
MediBotMediBot
Greetings! How can I assist you?MediBot
×

New Class of Antibiotics to Fight Drug Resistance Identified Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests